NeoGenomics Adds Flatiron Health Veteran Carolyn Starrett to Board
Event summary
- Carolyn Starrett, former CEO of Flatiron Health (2021–2025), joins NeoGenomics' board with expertise in AI-driven cancer care analytics.
- Starrett previously served on Foundation Medicine's board (2021–2024) and holds an MBA from Kellogg School of Management.
- Appointment underscores NeoGenomics' push to integrate real-world data and AI into oncology diagnostics.
The big picture
NeoGenomics' appointment of Carolyn Starrett reflects a broader industry trend toward AI-driven diagnostics and real-world data analytics in oncology. Her background at Flatiron Health, a leader in cancer care data insights, suggests the company is positioning itself to compete more aggressively in precision medicine. The move also signals a governance shift toward executives with deep expertise in healthcare technology convergence.
What we're watching
- AI Integration
- How Starrett's Flatiron Health experience will accelerate NeoGenomics' AI-driven diagnostic capabilities.
- Strategic Pivot
- Whether NeoGenomics can leverage real-world data insights to expand its oncology diagnostics portfolio.
- Board Influence
- The pace at which Starrett's governance impact materializes in NeoGenomics' operational strategy.
Related topics